{"analyses":[{"ciLowerLimit":"0.76","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.64","groupDescription":"Stratified Analysis","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.5798","paramType":"Hazard Ratio (HR)","paramValue":"1.11","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.80","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.72","groupDescription":"Unstratified Analysis","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.4035","paramType":"Hazard Ratio (HR)","paramValue":"1.18","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Upper limit not determined due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"19.06","upperLimit":"NA","value":"28.29"},{"groupId":"OG001","lowerLimit":"19.19","upperLimit":"30.52","value":"22.05"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"191"}],"units":"Participants"}],"description":"OS is defined as the time from randomization to death from any cause. Results from a pre-specified interim analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants will receive placebo matching to atezolizumab via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg/m\\^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Placebo and Paclitaxel"},{"description":"Participants will receive atezolizumab at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg per square meter (mg/m\\^2) via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.","id":"OG001","title":"Atezolizumab and Paclitaxel"}],"paramType":"MEDIAN","populationDescription":"PD-L1-positive subpopulation: participants in the ITT population whose PD-L1 status was IC1/2/3 at the time of randomization","reportingStatus":"POSTED","timeFrame":"From Day 1 to death from any cause, assessed up 36 months","title":"Overall Survival (OS) in the PD-L1-Positive Subpopulation","type":"SECONDARY","unitOfMeasure":"Months"}